BiosimilarDrug
QL1101 clinical trials
Also written QL1101.
A product of Bevacizumab; its studies count on that page too.
- studies test it
- 4
- open now
- 2
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the QL1101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 2
Qilu Pharmaceutical Co., Ltd. (2) · Sun Yat-sen University (1) · Yongpeng Wang (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses QL1101 is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingPhase 2Yongpeng WangNCT05585281Written as QL1101
- TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT05883176Written as Bevacizumab Biosimilar QL 1101
- A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy VolunteersCompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT06232902Written as QL1101
- Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerCompletedPhase 3Qilu Pharmaceutical Co., Ltd.NCT03169335Written as QL1101